{"brief_title": "Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)", "brief_summary": "To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)", "condition": ["Arthritis, Juvenile Rheumatoid"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["meloxicam oral suspension", "naproxen oral suspension"], "criteria": "Inclusion Criteria: - diagnosis of juvenile idiopathic arthritis (JIA) by International League of Associations for Rheumatology (ILAR) criteria; pauciarthritic, extended pauciarthritic, or polyarthritic current course of disease; - active arthritis of at least 2 joints - at least 2 other abnormal variables of the 5 remaining core set parameters - require nonsteroidal anti-inflammatory drugs (NSAIDs) - children aged 2-17 years Exclusion Criteria: - systemic course of juvenile idiopathic arthritis - all rheumatic conditions not included in inclusion criteria; any clinical finding or abnormal clinically relevant lab (not due to JIA) that could interfere with conduct of clinical trial - weight of 9 kg or less - pregnancy or breast feeding - females of childbearing potential who are sexually active and not using adequate contraception for at least 3 mos prior to and for duration of study - history of bleeding disorder, gastrointestinal bleeding, or cerebrovascular bleeding - peptic ulcer past 6 months - more than 1 disease modifying anti-rheumatic drug (DMARD) or change in DMARD during 3 months prior - change corticosteroids during 1 month prior - systemic corticosteroids greater than 10 mg/d, hydroxychloroquine greater than 10/mg/d, cyclosporine greater than 5 mg/kg/d., methotrexate greater than 15 mg/m2/wk, cytotoxic agents, gold, D-penicilamine, sulfasalazine, glucosamine, and investigational products - etanercept during 1 month prior; infliximab during 2 months prior; intra-articular corticosteroids during 1 month prior - patients requiring concomitant other NSAID including topical (excluding ophthalmic) - requirement for use of other NSAIDs, anticoagulants, phenothiazine, lithium, or ACTH - insufficient effect or intolerability to naproxen or meloxicam - known or suspected hypersensitivity to trial meds or their excipients - requirement of chronic H2 antagonist - history of asthma, nasal polyps, angioneurotic edema, or urticaria with aspirin or NSAIDs - planned surgical procedures during study - investigational drug exposure during this trial or within 30 days (or 6 half lives, whichever greater) prior - previous participation in this trial - patients with known drug or alcohol abuse - patient, parent or legal representative unable to understand and to comply with protocol", "gender": "All", "minimum_age": "2 Years", "maximum_age": "17 Years", "healthy_volunteers": "No", "mesh_term": ["Arthritis", "Arthritis, Rheumatoid", "Arthritis, Juvenile", "Meloxicam", "Naproxen"], "id": "NCT00034853"}